SEC Company Response from AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — Sep 22, 2017
AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: Sept. 22, 2017 · CIK: 0001385818 · Accession: 0001144204-17-049265
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220351
Referenced dates: September 12, 2017
Letter
AYTU BIOSCIENCE, INC.
373 Inverness Parkway, Suite 206
Englewood, CO 80112
September 22, 2017
Via Edgar
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Irene Paik
Mary Beth Breslin
Re: Aytu Bioscience, Inc.
Registration Statement on Form S-1
Filed September 5, 2017
File No. 333-220351
Ladies and Gentlemen:
Aytu Bioscience, Inc. (the “Company”), in connection with its filing of Amendment No. 1 to its Registration Statement on Form S-1, hereby responds to the Staff’s comments raised in the Staff’s letter dated September 12, 2017. For ease of reference, the Staff’s comments are reproduced below in their entirety, and the Company’s responses immediately follow.
Form S-1 filed September 5, 2017
Incorporation of Documents by Reference, page
1. Please revise this section to incorporate by reference all Current Reports on Form 8-K filed since the end of your fiscal year. See Item 12(a)(2) of Form S-1.
Response: The Company has revised to incorporate all current reports on Form 8-K filed since the end of the fiscal year.
General
2. We note that you have a pending request for confidential treatment. Please be advised that we will not be in a position to declare your registration statement effective until we resolve any issues concerning the confidential treatment request.
Response: The Company acknowledges the Staff’s comment.
Should you have any questions or comments with respect to the foregoing, please contact our counsel Marcelle S. Balcombe or Gregory Sichenzia at 212-930-9700.
Very truly
yours,
AYTU BIOSCIENCE,
INC.
Show Raw Text
CORRESP
1
filename1.htm
AYTU BIOSCIENCE, INC.
373 Inverness Parkway, Suite 206
Englewood, CO 80112
September 22, 2017
Via Edgar
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Irene Paik
Mary
Beth Breslin
Re: Aytu Bioscience, Inc.
Registration
Statement on Form S-1
Filed
September 5, 2017
File
No. 333-220351
Ladies and Gentlemen:
Aytu Bioscience, Inc. (the “Company”),
in connection with its filing of Amendment No. 1 to its Registration Statement on Form S-1, hereby responds to the Staff’s
comments raised in the Staff’s letter dated September 12, 2017. For ease of reference, the Staff’s comments are reproduced
below in their entirety, and the Company’s responses immediately follow.
Form S-1 filed September 5, 2017
Incorporation of Documents by Reference, page
50
1. Please revise this section to incorporate by reference
all Current Reports on Form 8-K filed since the end of your fiscal year. See Item 12(a)(2) of Form S-1.
Response:
The Company has revised to incorporate all current reports on Form 8-K filed since the end of the fiscal year.
General
2. We note that you have a pending request for confidential
treatment. Please be advised that we will not be in a position to declare your registration statement effective until we resolve
any issues concerning the confidential treatment request.
Response:
The Company acknowledges the Staff’s comment.
Should
you have any questions or comments with respect to the foregoing, please contact our counsel Marcelle S. Balcombe or Gregory Sichenzia
at 212-930-9700.
Very truly
yours,
AYTU BIOSCIENCE,
INC.
By:
/s/ Gregory Gould
Gregory Gould
Chief Financial Officer